Skip to main content

Roche Holding Value Stock - Dividend - Research Selection


ISIN: CH0012032048 , WKN: 855167

Market price date:
Market price:  

Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Key figures
Cash flow
Balance sheet
Income statement
Div. Yield%

Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.

Market Capitalization USD
Raw Data Source
Stock Split

Description of the company

At Roche, we believe in doing what should be done, rather than what has been done. So we follow where the science leads. We focus on today and look beyond tomorrow to tackle the world’s most formidable healthcare challenges.


Focus on medical need

Scientific breakthroughs are most likely to occur when scientists are free to tackle problems from different angles and in different ways. Our scientists have this freedom.


With radical scientific thinking and a deep understanding of disease mechanisms and therapies, we aim to produce the safest, most effective treatments available. Right now, we’re developing medicines in the areas where we see the greatest need:


In Oncology, our scientists are leaders in the identification of novel cell surface molecules and are working to characterise tumour antigens that may be useful in fighting various forms of cancer.


In Immunology, we’re constantly growing our expertise so that we can continue to discover and develop innovative medicines for patients living with debilitating diseases, such as rheumatoid arthritis or asthma.


Infectious diseases: Viral and bacterial infections are among the leading causes of disability and death. We’re committed to finding effective treatments for life-threatening infectious diseases.


In Neuroscience, we’re developing medicines for a range of serious brain diseases, including schizophrenia, Alzheimer’s disease, multiple sclerosis, depression, Parkinson’s disease, Down syndrome and autism.


Seeing the big picture

We make in vitro diagnostic tests for hospitals, commercial laboratories, physicians and patients. These can be used on blood, tissue or other patient samples to find and diagnose diseases and infections, select the right treatment and monitor how patients respond. Now, we’re able to test large numbers of samples in central labs faster, more reliably, and more efficiently than ever before. And more often than not, we can apply these new technologies at the earliest stages of targeted treatment development.


Collaboration is the key

Our greatest innovations grow from deep partnerships and collaboration with some of the smartest people and organisations in the industry. That’s how we’re building a better future for patients everywhere.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources::,,